Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has entered into a securities purchase agreement with institutional and accredited investors to sell 5,208,333 American Depositary Shares (ADSs) at $0.48 per ADS, along with accompanying Series A and Series B warrants. The company also executed a separate warrant inducement agreement with an existing investor. These combined transactions are expected to generate approximately $2.61 million in gross proceeds, with closing anticipated on or about April 27, 2026, subject to customary conditions.
The company plans to use the net proceeds to support the expansion of its contract development and manufacturing organization (CDMO) platform, advance customer programs, and continue investment in its immunotherapy pipeline. This funding is critical for Scinai as it seeks to scale its CDMO services and push forward its proprietary therapeutic candidates.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. Its pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. Additionally, the company owns Scinai Biopharma Services Ltd., a CDMO that provides development and manufacturing services to other biotechnology and pharmaceutical companies.
The private placement and warrant inducement highlight the company's strategy to secure non-dilutive and strategic capital to fund growth. For investors, this move signals Scinai's commitment to strengthening its operational capabilities and advancing its pipeline. The broader implications for the biotech industry include increased capacity for contract manufacturing, which can help other companies bring their therapies to market more efficiently.
For more details, the full press release is available at https://ibn.fm/6Vw4O. The latest news and updates relating to SCNI can be found in the company’s newsroom at https://ibn.fm/SCNI.
